Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report

By P. Malfertheiner, F. Mégraud, C. O'Morain, J. Gisbert, E. Kuipers, A. Axon, F. Bazzoli, Antonio Gasbarrini, J. Atherton, D. Y. Graham and 8 more. Gut, 2016

2,904 citations recorded by the source corpus.

Subfields: Epidemiology, Surgery

View Paper: https://www.semanticscholar.org/paper/1fa660e46e1457003a96e94bec3979e2622eb481

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Evelina Tacconelli

In Surgery

1. D. Graham
2. E. Kuipers
3. Evelina Tacconelli

Citations in the corpus

• Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions (2018, background): “HP infection causes chronic progressive gastric inflammation and a variety of diseases, including gastric and duodenal ulcers and gastric cancer.(3) In 1994 and 2009 the International Agency for Research on Cancer classified HP as a Group 1 carcinogen on the basis of a thorough review of relevant la”
• Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideli (2019, background): “pylori infection is now considered an infectious disease and eradication is recommended in most cases, regardless of the presence of precancerous conditions [156].”
• Antibiotics as Major Disruptors of Gut Microbiota (2020, background): “, proton-pump inhibitor, amoxicillin, clarithromycin, and metronidazole) therapies are recommended (Malfertheiner et al., 2017).”
• Helicobacter pylori infection (2013, positive): “pylori infection should undergo treatment to eradicate the pathogen (3).”